Stonebridge Capital Management Inc. Has $6.44 Million Position in Johnson & Johnson (NYSE:JNJ)

Stonebridge Capital Management Inc. lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 0.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 41,109 shares of the company’s stock after buying an additional 150 shares during the quarter. Johnson & Johnson comprises 3.1% of Stonebridge Capital Management Inc.’s portfolio, making the stock its 10th biggest holding. Stonebridge Capital Management Inc.’s holdings in Johnson & Johnson were worth $6,443,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Keener Financial Planning LLC bought a new stake in Johnson & Johnson during the 4th quarter worth about $40,000. WFA Asset Management Corp raised its holdings in Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson during the 4th quarter worth about $44,000. Disciplined Equity Management Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $45,000. Finally, Altshuler Shaham Ltd increased its stake in shares of Johnson & Johnson by 37.8% in the 3rd quarter. Altshuler Shaham Ltd now owns 317 shares of the company’s stock valued at $49,000 after acquiring an additional 87 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 0.1 %

Shares of NYSE JNJ traded up $0.09 during trading hours on Friday, hitting $145.54. The company had a trading volume of 4,075,342 shares, compared to its average volume of 7,121,075. The stock has a market capitalization of $350.27 billion, a P/E ratio of 9.07, a price-to-earnings-growth ratio of 2.42 and a beta of 0.53. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The firm’s 50 day moving average is $148.38 and its 200-day moving average is $154.71.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.68 EPS. On average, analysts expect that Johnson & Johnson will post 10.63 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.41%. The ex-dividend date was Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is 30.92%.

Analyst Ratings Changes

JNJ has been the subject of a number of recent analyst reports. Bank of America lowered their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 10th. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, June 4th. The Goldman Sachs Group initiated coverage on Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target for the company. Finally, HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price target for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Eight analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $174.07.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.